Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow PharmaCyte Biotech, Inc.

Get SEC filing alerts via email and in your feed for PharmaCyte Biotech, Inc.

PMCB

PharmaCyte Biotech, Inc.

About PharmaCyte Biotech, Inc.

PharmaCyte Biotech develops cellular therapies for cancer using proprietary live cell encapsulation technology, Cell-in-a-Box. Its focus includes treatments for pancreatic tumors, leveraging genetically engineered cells to activate prodrugs at tumor sites. The company aims to address unmet medical needs with targeted, minimally immunogenic therapies, operating within the biotech and cancer treatment markets, with a strong emphasis on regulatory compliance and intellectual property protection.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from PharmaCyte Biotech, Inc.

1
1
PharmaCyte Biotech, Inc. PharmaCyte Biotech Reports $1.6 Million Net Loss for Third Quarter, Focuses on Cancer Therapy Development

Via official filing (AI summary) | 3 months ago | 0 comments

2
1
PharmaCyte Biotech, Inc. PharmaCyte Biotech Reports $7.4 Million Net Loss for Quarter Ended October 31, 2025

Via official filing (AI summary) | 6 months ago | 0 comments

3
1
PharmaCyte Biotech, Inc. PharmaCyte Biotech Reports $8.36 Million Net Loss and Decreased Assets for Quarter Ended July 31, 2025

Via official filing (AI summary) | 9 months ago | 0 comments

4
1
PharmaCyte Biotech, Inc. PharmaCyte Biotech Reports No Revenue, $30.7M Net Income Due to Investments

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
PharmaCyte Biotech, Inc. PharmaCyte Biotech Reports Significant Turnaround in Net Income, Reduces Operating Expenses in Q2 2024

Via official filing (AI summary) | over 1 year ago | 0 comments